Business context and reporting period
This is Ocuphire Pharma, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2021—not a filing identified as Opus Genetics. Ocuphire is a clinical-stage ophthalmic biotech with no approved products. Its lead candidate Nyxol is being developed for several eye conditions; APX3330 is being studied for diabetic retinopathy. The company also holds licenses to APX2009 and APX2014.
Key financial metrics
| Metric | Three months ended September 30, 2021 | Nine months ended September 30, 2021 |
|---|---|---|
| Collaboration revenue | $489,000 | $589,000 |
| Operating expenses | $4.7 million | $17.1 million |
| Operating loss | $4.2 million | $16.6 million |
| Net loss | $4.2 million | $50.4 million |
| Net loss per share, basic and diluted | $0.25 | $3.64 |
Revenue consisted of license-related collaboration income, not product sales. Product gross margins are not applicable; the filing does not provide a clear operating-margin measure for this pre-commercial business. The nine-month net loss included a $33.8 million noncash expense from warrant-liability fair-value changes, which substantially increased reported loss.
At September 30, 2021, cash and cash equivalents were $22.25 million and short-term investments were $383,000; total current assets were $23.2 million versus current liabilities of $2.6 million. Total liabilities were $2.6 million, with no convertible notes outstanding. Stockholders’ equity was $20.6 million. Cash used in operations for the nine months was $13.7 million; financing provided $19.6 million, and cash increased $5.9 million. The company raised approximately $19.5 million net through a registered direct offering and its at-the-market program. It had 17,295,434 shares outstanding at quarter-end and 17,300,481 as of November 10, 2021.
Changes versus prior comparable periods
- Quarterly revenue increased from zero in Q3 2020 to $489,000; nine-month revenue rose from zero to $589,000, from BioSense and Processa license agreements.
- Quarterly operating expenses increased $2.8 million year over year, including higher R&D spending on clinical trials and manufacturing and higher public-company and administrative costs.
- Nine-month operating expenses increased $11.2 million year over year. R&D rose $8.1 million; the prior-year period included $2.1 million of acquired in-process R&D expense that did not recur.
- Nine-month net loss increased from $5.9 million to $50.4 million, mainly reflecting the $33.8 million warrant fair-value expense and increased operating costs. In February 2021, Series A warrants were reclassified from liabilities to equity after investors waived certain anti-dilution provisions; the warrants are no longer remeasured.
- Cash used in operations increased from $2.4 million to $13.7 million, while financing cash flow increased from $1.6 million to $19.6 million, principally from equity issuance.
Outlook, risks and unusual items
- Management expects losses and R&D expenses to increase as clinical development advances and says further capital will be needed. The company has no committed external funding source; management states that these conditions raise substantial doubt about its ability to continue as a going concern.
- Management expected Nyxol MIRA-3 and a pediatric MIRA-4 study to start in Q4 2021, with results expected in early 2022; LYNX-1 top-line results were expected in early 2022. A Nyxol NDA submission under the 505(b)(2) pathway was anticipated in late 2022, assuming successful and timely completion of the mydriasis trials.
- VEGA-1 presbyopia results were positive; the company was evaluating them and planning a Phase 3 program for the first half of 2022. APX3330 ZETA-1 top-line results were expected in the second half of 2022.
- COVID-19 could disrupt manufacturing, supply chains, clinical enrollment and regulatory work, and adversely affect liquidity and financing. Clinical, regulatory, manufacturing and financing timelines remain uncertain.
- Potential milestone and royalty payments under BioSense, Processa and Apexian agreements are contingent; no related license milestones were considered probable at quarter-end. Processa consideration included restricted shares valued at $342,000 and $200,000 cash. Payments under the legacy Rexahn licenses and Processa agreement are subject to a contingent value rights agreement with former Rexahn shareholders.
- In May 2021, Ocuphire issued 350,000 shares valued at $1.614 million to settle potential claims; the expense was recorded in general and administrative costs. Management reported no legal proceedings expected to have a material adverse effect and no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is for Ocuphire Pharma, Inc. (ticker OCUP), not Opus Genetics.
- Assess the going-concern warning, cash runway, operating cash burn and the company’s ability to obtain additional financing without substantial dilution.
- Track clinical-trial progress and whether the stated data, study-start and NDA timelines were achieved; these are forward-looking expectations, not guarantees.
- Review the composition of reported losses, particularly the noncash warrant fair-value charge, alongside recurring operating costs and cash use.
- Consider outstanding warrants and equity issuance capacity when evaluating potential dilution, and verify contingent payments or royalties as contractual milestones and sales develop.